The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors. METHODS: TS protein expression was determined in mCRC tissue. Patients who had TS-L tumors received FOLFOX/Bev, and those who had TS-H tumors were randomly assigned to receive either FOLFOX/Bev or IROX/Bev. The primary endpoint was the response rate (complete plus partial responses). RESULTS: In total, 211 of 247 patients (70% TS-H) were registered to the treatment phase. Efficacy analyses included eligible patients who had started treatment (N 5 186). The response rates for patients who received IROX/Bev (TS-H), FOLFOX/Bev (TS-H), and FOLFOX/Bev (TS-L) were 33%, 38%, and 49%, respectively (P 5 nonsignificant). The median progression-free survival (PFS) was 10 months (95% confidence interval [CI], 9-12 months; 10 months in the IROX/Bev TS-H group, 9 months in the FOLFOX/Bev TS-H group, and 13 months in the FOLFOX/Bev TS-L group). The TS-L group had improved PFS compared with the TS-H group that received FOLFOX/Bev (hazard ratio, 1.6; 95% CI, 1.0%-2.4%; P 5 .04; Cox regression). The median overall survival (OS) was 22 months (95% CI, 20 29 months; 18 months in the IROX/Bev TS-H group, 21 months in the FOLFOX/Bev TS-H group, and 32 months in the TS-L group). OS comparisons for the 2 TS-H arms and for the FOLFOX/Bev TS-H versus TS-L arms were not significantly different. CON-CLUSIONS: TS expression was prognostic: Patients with TS-L tumors who received FOLFOX/Bev had a longer PFS than those with TS-H tumors, along with a trend toward longer OS. Patients with TS-H tumors did not benefit more from IROX/Bev than from FOL-FOX/Bev. Cancer 2018;124:688-97.
INTRODUCTION
Thymidylate synthase (TS) plays a central role in providing thymidine triphosphate for DNA synthesis and repair and is an important intracellular target of 5-fluorouracil (5-FU). Inhibition of TS results in accumulation of intracellular deoxyuridine monophosphate; both deoxyuridine triphosphate and fluorodeoxyuridine triphosphate are misincorporated into DNA, causing direct damage and interference with repair. 1, 2 Several studies reported that tumors with low TS expression (TS-L) was associated with a higher response rate to 5-FU-based therapy than tumors with high TS expression (TS-H). [3] [4] [5] [6] [7] [8] [9] [10] We hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with TS-H protein expression would have a lower overall response rate (complete responses [CRs] 1 partial responses [PRs] ) to treatment with combined 5-FU, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with TS-L tumors. 11, 12 In addition, we hypothesized that cancers with TS-H expression would have a higher response rate with a nonfluoropyrimidine regimen (irinotecan and oxaliplatin [IROX]/Bev) compared with FOLFOX/Bev. 13 The objectives of the current trial were to evaluate the response rates of patients with mCRC who received treatment with either FOLFOX/Bev or IROX/Bev; to compare the response rates, progression-free survival (PFS), overall survival (OS), and toxicity of patients with TS-H tumor expression who received either FOLFOX/Bev or IROX/Bev; and to compare these parameters in patients who had TS-H tumors versus those who had TS-L tumors among those who received treatment with FOLFOX/Bev.
MATERIALS AND METHODS

Eligibility
Eligibility criteria included patients aged 18 years who had mCRC and had received no prior therapy for metastatic or locally recurrent disease, measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2, an absolute neutrophil count >1500/lL, platelets >100,000/lL, total bilirubin <1.5 mg/dL, aspartate and alanine aminotransferase levels <3 times the upper limits of normal, normal serum creatinine, and an international normalized ratio (INR) <1.5, unless the patient was receiving full-dose anticoagulation therapy. No patient could have a myocardial infarction, New York Heart Association class III or IV myocardial disease, or unstable angina within 6 months of study entry. Patients could not have symptomatic arrhythmia, a history of significant peripheral artery disease, or grade 2 or worse peripheral neuropathy. No history of stroke or transient ischemic attack within 6 months of study entry was permitted. Pregnant or breast-feeding women were excluded. Prior adjuvant therapy was permitted if it was completed 12 months before enrolling in the current study. Institutional Review Board approval was obtained and written informed consent was required for all patients.
Design Summary
Tissue submission from metastatic tumor to the ECOG/ ACRIN (American College of Radiology Imaging Network) Pathology Coordinating Office was mandatory for registration before treatment assignment: In step 1, treatment assignment was based on TS expression in recurrent or metastatic tumor measured by immunohistochemical staining, as previously described. 14, 15 Patients moved to step 2 once tumor TS expression was determined. Those with TS-H expression (21 or higher) were randomized equally using a permuted blocks algorithm to 1 of 2 treatment arms: IROX/Bev or FOLFOX/Bev. Those with TS-L expression (0 or 11) or indeterminate TS expression (the sample contained no tumor, had an insufficient cell number, or was deemed to be not evaluable) were assigned to FOLFOX/Bev. In all 3 arms, patients received Bev 5 mg/kg intravenously over 30 to 90 minutes. In arm A, IROX/Bev involved oxaliplatin 65 mg/m 2 delivered intravenously 120 over minutes, then irinotecan 120 mg/m 2 delivered intravenously over 90 minutes. 11, 13 In arm B, FOLFOX/Bev consisted of oxaliplatin 85 mg/m 2 given with leucovorin 400 mg/m 2 delivered intravenously over 120 minutes, then 5-FU bolus 400 mg/m 2 and 5-FU infusion 2400 mg/m 2 over 46 hours. 12, 13 In arm C, FOL-FOX/Bev was used at same doses as arm B. Each cycle consisted of treatment on days 1 and 15 of a 28-day cycle. Dose modifications are provided in the Supporting Methods (see online supporting information).
Immunohistochemical Method for TS Protein Expression
The specimens were analyzed in the ECOG Central Pathology Office at Northwestern University Medical Center according to method described by Allegra et al. 16 Details of the method are provided in the Supporting Methods (see online supporting information).
Statistical Considerations
The sample size was determined based on tumor TS-L and TS-H expression. Patients with indeterminate TS expression were entered on arm C but were excluded in the power calculations for the primary analysis. We expected that 144 patients with TS-H expression would be randomized equally to arm A or B, with the expectation that 138 (69 per arm) would be eligible. We also expected that 98 patients with TS-low/TS-indeterminate expression would be assigned to treatment (arm C) with the expectation that 87 with TS-L expression would be eligible. In total, 246 patients (236 eligible, including 69 on arms A and B and 98 on arm C) would be entered onto Therapy by Thymidylate Synthase Content/Meropol et al Cancer February 15, 2018 this trial in a 2-stage design, with 117 patients in the first stage. A planned interim analysis for response determination occurred after the accrual of 121 patients registered to the treatment phase. Additional information regarding the statistical design can be found in the Supporting Methods (see online supporting information). After this assessment, all 3 arms of the study were reopened in an effort to provide more precision on the estimates of response rates and narrow the confidence intervals (CIs).
Toxicities were assessed using the National Cancer Institute Common Toxicity Criteria, version 3.0. Objective tumor response, categorical patient characteristics, and toxicity were compared using Fisher exact tests with a 2-sided significance level of .05. 17 Continuous patient characteristics were compared using Kruskal-Wallis tests. OS was defined as the time from registration on step 2 of the study until death (event) or was censored at the last known date of survival. PFS was defined as the time from registration on step 2 of the study to disease progression or death without evidence of progression. For patients without documentation of progression, follow-up was censored on the date of last disease assessment without progression, unless death occurred within a short time (4 months) after the date patient was last known progression-free, in which case the death was counted as an event. OS and PFS were estimated using the KaplanMeier method, with 95% CIs calculated using the Greenwood formula, and were compared using the logrank test. 17, 18 Cox regression models of OS and PFS were used to provide hazard ratio estimates and associated inferences with the Wald test. 19 All P values reported were for 2-sided significance tests, and P values < .05 were considered significant.
RESULTS
Patient Characteristics
This study was active between July 2005 and April 2012. Accrual was 247 patients to step 1 and 211 patients (TS-H, 70%; TS-L/TS-indeterminate, 30%) to the treatment phase, of whom 186 patients who were deemed eligible started treatment. Two hundred forty-seven patients were registered to step 1: 36 did not go on to step 2; 9 were ineligible, 6 withdrew or were never registered, 3 had unknown TS status; 2 had either disease progression or a decline in performance status, 15 with TS-L could not enter step 2 because arm C was suspended, and 1 patient had no insurance. Overall, 211 patients were registered to step 2. Efficacy analyses included eligible patients who started treatment (N 5 186), and the safety analysis (toxicity) included all patients who started treatment (N 5 205). Seventy-three patients were randomized to arm A; including 70 who received treatment, and 9 who were deemed ineligible for the following reasons: 6 had a baseline scan >4 weeks before randomization, 1 had nonmeasurable disease, 1 had an absolute neutrophil count <1500/lL, and 1 had another reason. Three patients did not receive treatment because of ineligibility (n 5 2) or insurance denial (n 5 1). Seventy patients were analyzed for toxicity, and 61 were analyzed for efficacy. Of 75 patients who were randomized to arm B, 73 received treatment. Of these, 7 were deemed ineligible for the following reasons: 6 had baseline scans >4 weeks before randomization, and 1 had an elevated bilirubin. Two patients refused treatment. Seventy-three patients were analyzed for toxicity, and 66 were analyzed for efficacy. Of 63 patients allocated to arm C, 62 received therapy, and 3 were deemed ineligible because of baseline scans >4 weeks before randomization. One patient refused therapy. Sixtytwo patients were analyzed for toxicity, and 59 were analyzed for efficacy. There were 5 patients with TSindeterminate expression levels (2.4%).
Among all 186 eligible and treated patients, 127 had TS-H expression (68%), and 59 had TS-L/TS-indeterminate expression (32%). The demographics are provided in Table 1 . There was a higher proportion of patients with a performance of zero (59.1%) in the FOLFOX/Bev TS-H group (P 5 .03) compared with 39.3% in the IROX/Bev TS-H group and 40.7% in the FOLFOX/Bev TS-L group. Race, age, sex, and disease status were not statistically different among the treatment arms. Less than 10% of patients had received prior adjuvant therapy. Greater than 80% had liver metastasis, approximately 30% had lung or lymph node metastasis, and <10% had bone or peritoneal metastasis. Information on the location of the primary tumor was not recorded. The tumor characteristics did not differ statistically among the treatment arms.
Clinical Outcomes
The median number of treatment cycles was 6 for all arms (range, 1-32 treatment cycles). The distribution of the reasons for treatment termination varied significantly among the 3 arms (P 5 .02). A higher proportion of patients stopped treatment because of progressive disease and died on study in the IROX/Bev TS-H arm (Table 2) , and a higher proportion of patients stopped for toxicity/ side effects in the FOLFOX/Bev TS-H group. Point estimates for the response rate favored the FOLFOX/Bev arms, with the highest response rate of 49% in the TS-L group (Table 2) . However, no statistically significant differences in preplanned objective response rate comparisons were observed in the 2 comparisons TS-H (IROX/Bev vs FOLFOX/Bev) or FOLFOX/Bev (TS-H vs TS-L). FOLFOX/Bev) and the FOLFOX/Bev groups (TS-H vs TS-L). However, there were differences in the proportion of patients with grade 3 diarrhea for the 2 comparisons, with higher toxicity observed in those with TS-L tumors than in those with TS-H tumors who received FOLFOX/ Bev; patients with TS-H tumors who received IROX/Bev also had a higher incidence of grade 3 diarrhea than those with TS-H tumors who received FOLFOX/Bev. Eleven patients (5.9%) experienced lethal events, and it was believed that 10 of those 11 events were related to underlying colorectal cancer rather than treatment-associated toxicity. Twenty-six patients underwent subsequent surgery. A higher proportion of patients with TS-L patients who received FOLFOX/Bev underwent postchemotherapy surgery (P 5 .030; chi-square test). Because this was not a study endpoint, specific details on the nature and outcome of the surgeries are not available.
Overall and Progression-Free Survival
Among 182 patients who were evaluable for the PFS analysis, in total, there were 142 events, including 125 deaths.
The overall PFS and OS were 10 months (95% CI, 9-12 months) and 22 months (95% CI, 20-29 months), respectively. Median PFS and OS rates for the 3 arms are provided in Table 5 . In both treatment arms, PFS was superior in patients who had TS-L tumors compared with Original Article those who had TS-H tumors. Figure 1 illustrates the KaplanMeier PFS and OS curves according to treatment arm. If the 5 patients with indeterminate TS evaluations are excluded from the TS-L cohort, then the median PFS for patients who had TS-L tumors was 13 months (95% CI, 10-18 months); the 2-sided log-rank test indicated significant differences between the TS-L and TS-H groups that received FOLFOX/Bev (P 5 .02). The median OS for FOLFOX/Bev in the TS-L only patients was 35 months (95% CI, 23-45 months); and the 2-sided long-rank test indicated significant differences between the 2 TS groups that received FOLFOX/Bev in favor of the TS-L group. (P 5 .03). The objective response rate (1 CR and 25 PRs) among 54 TS-L-only patients was 48% (95% CI, 38%-61%). No differences in the FOLFOX/ Bev arms were observed according to TS status (P 5 .17; Fisher exact test).
An intent-to-treat analysis that used all 211 patients and included the patients who were ineligible or refused treatment is provided in Table 6 . Among those who received FOLFOX/Bev, the TS-L group had a significantly longer PFS in both log-rank and Cox analyses, whereas OS became significant using the log-rank test and was marginally significant in Cox analysis. DISCUSSION TS-L protein expression was associated with longer PFS among patients who had TS-L tumors versus TS-H tumors and received treatment with FOLFOX/Bev. Point estimates for response rates and OS also favored patients with TS-L tumors, although these differences were not statistically significant in this small phase 2 trial. The hypothesis that resistance to 5-FU in TS-H tumors would favor treatment with the non-5-FU-containing regimen IROX was not supported. Formal testing of the hypothesis that TS-L is associated with predicting a response to 5-FU would have required an additional randomization of patients with TS-L tumors to a non-5-FU regimen.
This study demonstrated the feasibility of determining TS protein expression in tissue from patients with mCRC in real time before treatment assignment. Protein expression, rather than messenger RNA expression, was used in the current study for the following reasons: Protein expression is the final denominator in gene expression. We believed that the use of paraffin-embedded tissue eased the logistic considerations for this multicenter study, because routine methods of sample preparation, analysis, and shipment could be used. To enroll in this study, patients must either have had access to a previously obtained biopsy of a metastatic site (paraffin-embedded) or be would be willing to undergo biopsy of a metastatic site, because treatment assignment was based on intratumor TS expression. Comparison of TS expression in primary versus metastatic tumors was not performed in this study. The design of this study did not take into account the possible heterogeneity in TS protein expression in different sites of metastatic disease, although obtaining multiple biopsies from more than 1 site was not feasible. Kumamoto and colleagues reported a weak correlation in TS messenger RNA expression between primary and metastatic liver lesions (r 5 0.57; Spearman rank correlation; n 5 30). 24 The correlation was better for synchronous liver metastasis (r 5 0.71; n 5 15) than for metachronous liver metastasis (r 5 0.53; n 5 15). TS protein expression was not studied.
At the time this study was designed, we anticipated a 10% improvement in the response rate with the addition of Bev to chemotherapy 20, 21 ; however, not all Bev combinations exhibit such an increment. Subsequent trials comparing 3-drug combination regimens such as FOLFOX or FOLFIRI (irinotecan/5-FU/leucovorin) with Bev indicated no substantial increase in the response rate with the addition of Bev. 22, 23 At interim analysis, the overall response rate for the study population was lower than anticipated. A modified study design allowed expanded accrual to all 3 arms. Patients who had TS-L tumors had trends toward a higher response rate (CR 1 PR; 49% vs 38%; P 5 .07), longer PFS (13 vs 9 months; P 5 .04), and longer OS (32 vs 21 months; P 5 .07) with FOL-FOX/Bev compared with patients who had TS-H tumors.
In a post-hoc intent-to-treat analysis that included all 211 patients, the median OS for the 3 arms was 20, 21, and 32 months for arms A, B, and C, respectively. The 2-sided log-rank tests indicated no significant differences in OS between the 2 TS-H arms (P 5 .22), but a significant difference was observed in OS between the 2 FOLFOX/ Bev arms in favor of patients who had TS-L tumors (P 5 .04). The intent-to-treat analysis was not prespecified in the protocol; therefore, interpretation of the P values must be viewed cautiously. However, the reason that 15 of 21 patients (71%) were deemed on audit to be ineligible for stage 2 of the study was that they had an interval <28 days for baseline Response Evaluation Criteria in Solid Tumors (RECIST) scan and the initiation of study therapy. These 15 patients received the chemotherapy as specified on the protocol. This issue may inform the design of future studies that use real-time analysis of a biomarker for treatment assignment or randomization.
It is possible that, with the addition of agents to 5-FU/leucovorin, TS expression is less important as a predictive factor than when patients receive 5-FU alone. 5-FU also mediates cytotoxicity by the misincorporation of fluorouridine triphosphate into all forms of RNA and interference with RNA function; these mechanisms do not rely on TS. 7 The incidence of grade 3 diarrhea (11%) was higher in the patients who had TS-L tumors compared with those who had TS-H tumors (1%) and received FOLFOX/Bev. This finding is consistent with the hypothesis that patients whose tumors have TS-L content may also have TS-L expression in normal organs and thus may be at risk for increased host toxicity. Patients with TS-H tumors appeared to have a comparable benefit with IROX/Bev and FOLFOX/Bev, although the incidence of grade 3 diarrhea was greater with IROX/Bev. In Cancer and Leukemia Group B study 9741, IROX was associated with a time to progression of 6.7 months and an OS of 17.3 months in patients with colorectal cancer whose TS status was not determined. 9 By comparison, patients with TS-H tumors who received IROX in the current study appeared to have better outcomes (time to progression, 9 months; OS, 20 months), although interstudy comparisons must be considered with caution. Our data do not support the routine use of IROX, and its role is likely limited to therapy for patients who do not tolerate fluoropyrimidines.
To our knowledge, this was the first prospective trial to use TS as a determinant of treatment assignment for patients with advanced colorectal cancer. The data support the value of TS as a prognostic biomarker of 5-FU benefit. Patients with TS-L tumors derive considerable benefit with FOLFOX/Bev. However, the results indicate that patients who have mCRC with TS-H tumors need not avoid 5-FU-based therapy. 5-FU remains an integral component of systemic therapy for mCRC, and studies have demonstrated the clinical synergy of 5-FU combined with oxaliplatin and irinotecan. High TS levels in tumor tissue do not appear to predict a complete lack of benefit from fluoropyrimidine combination chemotherapy. It remains plausible that TS-L tumors have increased sensitivity to fluoropyrimidine therapy compared with TS-H tumors; although, our study design did not permit a definitive assessment of this hypothesis. TS also may be an indicator for other key determinants of cancer biology and has demonstrated independent prognostic importance in patients with locally advanced colon and rectal cancers. 16, [25] [26] [27] Pharmacodynamic and pharmacogenomic studies may also provide useful and complementary information to ultimately guide treatment selection.
With the increasing complexity of chemotherapy regimens, it may be more difficult to conduct prospective studies of biomarker-selected treatment unless the biomarker is associated with a clear-cut binary outcome (possibility of benefit vs no possibility of benefit). Currently, such biomarkers include a wild-type, expanded RAS panel to select patients for anti-EGFR therapy or microsatellite instability-high/mismatch repair-deficient status to select patients for treatment with immune check-point inhibitors. 27, 28 Emerging clinical data further attest to the inhomogeneity of mCRC, such as location of the primary tumor. 29 Although biomarker development is often focused on newer "targeted" therapeutics, our data highlight the recognition that traditional cytotoxics like 5-FU also have targets with variable expression that may influence treatment outcome and should be further developed for clinical use. 
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